Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173362 · ClinicalTrials.gov registry record · Phase 2
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
A Phase 2 study of Stage IV Prostate Cancer AJCC v8 and Stage III Prostate Cancer AJCC v8, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT06173362 is a Phase 2 study of Stage IV Prostate Cancer AJCC v8 and Stage III Prostate Cancer AJCC v8 that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 75 participants, below the 153-participant average among 28 other Stage IV Prostate Cancer AJCC v8 trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06173362, a Phase 2 study of Stage IV Prostate Cancer AJCC v8 and Stage III Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Androgens (male hormones) can cause the growth of prostate tumor cells. Abiraterone acetate lowers the amount of androgens made by the body. This may help stop the growth of prostate tumor cells that need androgen to grow. Darolutamide blocks the use of androgens by the tumor cells. Prednisone is used to lessen inflammation and lower the body's immune response. Researchers want to compare the side effects of standard of care (SOC) abiraterone and prednisone or darolutamide alone in treating patients with advanced prostate cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- DRUG Darolutamide
- DRUG Prednisone
- DRUG Abiraterone
Study Locations (1)
California
- University of California Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06173362
The ClinicalTrials.gov registry entry for NCT06173362 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 153-participant average among 28 other Stage IV Prostate Cancer AJCC v8 trials with a reported enrollment target (51% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage IV Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT06173362 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06173362 about?
NCT06173362 is a clinical study titled "Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer". This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Androgens (male hormones) c...
What is the current status of trial NCT06173362?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2023-11-09. Estimated completion is 2027-05.
What conditions does trial NCT06173362 study?
This clinical trial studies the following conditions: Stage IV Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Advanced Prostate Adenocarcinoma.
What interventions are being tested in trial NCT06173362?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Darolutamide (DRUG), Prednisone (DRUG), Abiraterone (DRUG).
Who is sponsoring clinical trial NCT06173362?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06173362 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Prostate Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
RECRUITING · Phase 2
-
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
RECRUITING · Phase 2
-
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
RECRUITING · Phase 2
-
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Stage IV Prostate Cancer AJCC v8
All registered trials for this condition
Stage III Prostate Cancer AJCC v8
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.